<code id='1002C235E0'></code><style id='1002C235E0'></style>
    • <acronym id='1002C235E0'></acronym>
      <center id='1002C235E0'><center id='1002C235E0'><tfoot id='1002C235E0'></tfoot></center><abbr id='1002C235E0'><dir id='1002C235E0'><tfoot id='1002C235E0'></tfoot><noframes id='1002C235E0'>

    • <optgroup id='1002C235E0'><strike id='1002C235E0'><sup id='1002C235E0'></sup></strike><code id='1002C235E0'></code></optgroup>
        1. <b id='1002C235E0'><label id='1002C235E0'><select id='1002C235E0'><dt id='1002C235E0'><span id='1002C235E0'></span></dt></select></label></b><u id='1002C235E0'></u>
          <i id='1002C235E0'><strike id='1002C235E0'><tt id='1002C235E0'><pre id='1002C235E0'></pre></tt></strike></i>

          fashion

          fashion

          author:fashion    Page View:11755
          Bristol Myers Squibb sign
          Courtesy Bristol Myers Squibb

          Bristol Myers Squibb will pay $4.1 billion for RayzeBio, the companies said Tuesday, buying into the fast-growing field of using targeted doses of radiation to treat cancer.

          RayzeBio, which raised about $350 million in a September initial public offering, is working in radiopharmaceuticals, which pair the tumor-killing power of radiation with the precision of targeted cancer therapies. The company is currently running a pivotal trial of its most advanced drug, RYZ101, in neuroendocrine cancer and has a pipeline of treatments for kidney, liver, and other cancers.

          advertisement

          Bristol Myers will pay $62.50 in cash per share of RayzeBio, a roughly 115% premium to the company’s recent trading and more than triple the company’s IPO price.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia

          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more
          Experts study whether long Covid risk adds up with each reinfection
          Experts study whether long Covid risk adds up with each reinfection

          AstudyfromZiyadAl-Aly,clinicalepidemiologistatWashingtonUniversityinSt.Louis,showedthatvaccinationap

          read more
          Bright Health sells Medicare Advantage business to Molina
          Bright Health sells Medicare Advantage business to Molina

          BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

          read more

          Will an HIV vaccine ever be a reality?

          LabworkattheAIDSVaccineDesignandDevelopmentLaboratoryinBrooklyn.ChrisHondros/GettyImagesLouisPickeri